Adamgammadex Sodium Approved by NMPA: The World’s Second and China’s First Homegrown Targeted Neuromuscular Block Reversal Agent
On July 1, China’s National Medical Products Administration (NMPA) approved Adamgammadex Sodium Injection for marketing. Adamgammadex sodium approved by NMPA marks a major milestone as the world’s second and China’s first domestically developed targeted neuromuscular block reversal agent.
For many years, the global market for targeted neuromuscular block reversal agents has been dominated by Merck’s Sugammadex.
Adamgammadex Sodium Injection is a Class 1 innovative drug jointly developed by Adamerck Pharmlabs and Xianju Pharmaceutical. Its approval provides a new Chinese innovation for reversing rocuronium-induced neuromuscular blockade.
In this article, DengYueMed introduces the mechanism of action of Adamgammadex Sodium, the Phase III clinical trial results, the differences between Adamgammadex Sodium vs Sugammadex Sodium, and its future market prospects.
The Role of Neuromuscular Block Reversal Agents in Perioperative Anesthesia
Neuromuscular blocking agents are essential medications during general anesthesia, allowing skeletal muscles to relax for endotracheal intubation and surgical procedures.
At the end of surgery, timely reversal of neuromuscular blockade is critical for patient safety and postoperative recovery. The major benefits include: 🔽
- Reducing the risk of residual neuromuscular blockade: Helping patients regain spontaneous breathing and muscle strength more quickly.
- Lowering perioperative complications: Reducing the risk of postoperative airway obstruction, hypoxemia, and other respiratory complications.
- Improving anesthesia recovery quality: Promoting neuromuscular recovery and enhancing perioperative anesthesia management.
- Meeting growing clinical demand: As the number of surgeries under general anesthesia continues to increase, safe and effective targeted reversal agents have become an important focus in anesthesiology.
Against this background, Adamgammadex sodium approved by NMPA offers a new domestically developed option for reversing rocuronium-induced neuromuscular blockade, further expanding China’s perioperative anesthesia treatment options.
What Is Adamgammadex Sodium?
Adamgammadex Sodium Injection is a targeted neuromuscular block reversal agent indicated for the reversal of rocuronium-induced neuromuscular blockade after general anesthesia.
It helps patients recover spontaneous respiration and muscle function more rapidly while reducing the risk of postoperative residual neuromuscular blockade.
Drug Overview
| Item | Details |
|---|---|
| Drug Name | Adamgammadex Sodium Injection |
| Chinese Name | 阿更葡糖钠注射液 |
| Brand Name | 奥美克松®/Aomeikesong® |
| Developers | Adamerck Pharmlabs & Xianju Pharmaceutical |
| Approval Date | July 1, 2026 |
| Regulatory Authority | National Medical Products Administration (NMPA) |
| Drug Class | Targeted neuromuscular block reversal agent |
| Indication | Reversal of rocuronium-induced neuromuscular blockade |
Adamgammadex sodium approved by NMPA represents the world’s second targeted neuromuscular block reversal agent and the only domestically developed product of its kind in China. It is a next-generation molecule optimized from the structural design of Sugammadex.
What Are the Technological Innovations of Adamgammadex Sodium?
Rather than being a simple copy of Sugammadex, Adamgammadex Sodium is considered a “me-better” innovative drug, featuring meaningful molecular improvements.
Optimized Molecular Structure
Sugammadex is built on a γ-cyclodextrin core structure. Adamgammadex Sodium introduces an innovative modification by replacing the α-carbon of the carboxylic acid side chain with a chiral acetamide group.
This structural optimization helps shield the carboxyl group associated with hypersensitivity reactions while strengthening its binding affinity for rocuronium.
The improved molecular design maintains rapid reversal capability and may also contribute to an improved safety profile.
Targeted Reversal of Neuromuscular Blockade
Adamgammadex Sodium rapidly encapsulates circulating rocuronium molecules, rendering them inactive and thereby reversing neuromuscular blockade.
Unlike traditional cholinesterase inhibitors, its mechanism does not depend on increasing acetylcholine levels. Instead, it directly binds the neuromuscular blocking agent, allowing faster and more precise recovery.
Phase III Clinical Trial Results Supporting Adamgammadex Sodium Approved by NMPA
The approval of Adamgammadex sodium approved by NMPA was primarily supported by two pivotal Phase III clinical studies. Among them, CTR20211477 was a multicenter, randomized, double-blind, active-controlled, non-inferiority Phase III trial.
Study Design
The study enrolled 310 patients undergoing elective surgery.
Participants received either:
- Adamgammadex Sodium 4 mg/kg
- Sugammadex 2 mg/kg
The study compared the efficacy and safety of both drugs for reversing rocuronium-induced neuromuscular blockade.
Primary endpoints included neuromuscular recovery, recovery time, and overall safety.
Efficacy Results
The study demonstrated that 98.7% of patients receiving Adamgammadex Sodium achieved a TOF ratio ≥0.9 within five minutes, meeting the predefined non-inferiority criteria compared with Sugammadex.
Recovery was rapid in both groups.
The median time to achieve a TOF ratio of 0.9 was:
- Adamgammadex Sodium: approximately 2.25 minutes
- Sugammadex: approximately 1.75 minutes
These findings confirmed that Adamgammadex Sodium provided rapid and reliable reversal of neuromuscular blockade while meeting the predefined efficacy objectives.
Safety Profile
Safety analysis showed encouraging results across several adverse events of special interest.
Compared with Sugammadex, the Adamgammadex Sodium group demonstrated lower incidences of:
- Hypersensitivity reactions
- Recurarization
- Bradycardia
- Laryngospasm and bronchospasm
The Phase III findings suggest that Adamgammadex Sodium has a favorable overall safety profile and provides an additional treatment option for perioperative patients.
Adamgammadex Sodium vs Sugammadex Sodium
Although both medications are targeted neuromuscular block reversal agents, they differ in development history, molecular design, and certain clinical characteristics.
| Comparison | Adamgammadex Sodium | Sugammadex Sodium |
|---|---|---|
| First Approval | China (2026) | European Union (2008) |
| Drug Class | Targeted neuromuscular block reversal agent | Targeted neuromuscular block reversal agent |
| Molecular Design | Optimized γ-cyclodextrin structure | γ-cyclodextrin structure |
| Developer | Adamerck Pharmlabs | Merck |
| Clinical Features | Maintains rapid reversal with encouraging safety outcomes | Extensive global clinical experience |
| Patent Status | Under patent protection | Core patents have expired or are expiring in multiple countries |
Both drugs have well-established clinical value, and treatment decisions should always be based on individual patient conditions and physician judgment.
Market Significance and Future Outlook of Adamgammadex Sodium Approved by NMPA
The fact that Adamgammadex sodium approved by NMPA represents not only a milestone for Adamerck Pharmlabs but also another important breakthrough in China’s anesthesia drug innovation.
Its approval brings multiple benefits:
- For clinicians: More options for neuromuscular block reversal therapy.
- For patients: Greater access to innovative perioperative medications.
- For the pharmaceutical industry: Stronger evidence of China’s growing capability to develop innovative medicines in technically demanding therapeutic areas.
As overseas clinical development and international regulatory registration progress, Adamgammadex Sodium is expected to strengthen its position in the global market and offer more innovative solutions for perioperative anesthesia management.
Conclusion
Adamgammadex sodium approved by NMPA marks an important breakthrough in the field of targeted neuromuscular block reversal agents and introduces a new Chinese innovation for reversing rocuronium-induced neuromuscular blockade.
From its optimized molecular design and pivotal Phase III clinical studies to its future international development strategy, Adamgammadex Sodium demonstrates the growing strength of Chinese pharmaceutical innovation in anesthesiology.
DengYueMed, a China pharmaceutical wholesaler, closely follows Chinese innovative drug approvals and industry developments, providing timely insights for healthcare institutions, pharmacies, and global partners.
FAQ about Adamgammadex Sodium Approved by NMPA
What is Adamgammadex Sodium?
Adamgammadex Sodium is a targeted neuromuscular block reversal agent approved in China for reversing rocuronium-induced neuromuscular blockade after general anesthesia.
Why is Adamgammadex Sodium approved by NMPA significant?
Its approval marks the launch of the world’s second and China’s first domestically developed targeted neuromuscular block reversal agent.
How does Adamgammadex Sodium work?
It rapidly binds to rocuronium molecules in the bloodstream, reversing neuromuscular blockade without inhibiting cholinesterase.
What is the difference between Adamgammadex Sodium and Sugammadex?
Both are targeted reversal agents, but Adamgammadex Sodium features an optimized molecular structure developed in China while demonstrating non-inferior efficacy in Phase III clinical trials.
What is Adamgammadex Sodium used for?
It is indicated for reversing rocuronium-induced neuromuscular blockade in patients undergoing general anesthesia, helping restore muscle function and spontaneous breathing.
